The authors introduced a novel “all-in-one nanosoldier” made of colloidal hybrid nanostructures, which were designed for simultaneously targeting, imaging, and killing TNBC cells. The results demonstrated that this novel strategy was highly effective for targeting and killing TNBC cells in vitro, expressing high levels of folate membrane-receptors.
[Journal of Materials Chemistry B]
[zotpress userid=’6606345′ items=’M5TS5KL4′ style=’apa’ cite=’yes’]
Scientists report new non-canonical regulatory properties of ultra-selective histone deacetylase inhibitors over the expression and function of epithelial-mesenchymal transition pathways and the invasiveness potential of breast cancer.
[zotpress userid=’6606345′ items=’H9X2UITC’ style=’apa’ cite=’yes’]
Scientists presented an alternate method to culture individually selected cells in relative isolation from the rest of the population under physiologically relevant matrix conditions. Using examples of breast and colorectal cancers, scientists showed that individual cells evolve into tumors or aspects of tumors displaying different characteristics of the initial cancer type and aggressiveness.
[zotpress userid=’6606345′ items=’AZ9TJVLH’ style=’apa’ cite=’yes’]
Investigators demonstrated that the histone binding function of Pygo2 was important for driving de-differentiation and malignancy of breast tumors, and loss of this binding activated various differentiation pathways which attenuated primary tumor growth and metastasis formation.
[zotpress userid=’6606345′ items=’8TU7CT2A’ style=’apa’ cite=’yes’]
Oncolytics Biotech® Inc announced a new investigator-sponsored triple-negative breast cancer study to be managed by Rutgers Cancer Institute of New Jersey. The phase II trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte’s anti-PD-1 checkpoint inhibitor retifanlimab in patients with unresectable locally advanced or metastatic TNBC.
Researchers designed a mitochondrial targeted drug delivery system based on N-(2-hydroxypropyl) methacrylamide copolymers to simultaneously inhibit breast cancer progression and metastasis.
[Journal of Controlled Release]
[zotpress userid=’6606345′ items=’GX2U6XSL’ style=’apa’ cite=’yes’]
Researchers demonstrated that exposure to mechanical strain promoted invasive and pro-tumorigenic phenotypes in breast cancer cells, indicating that mechanical strain could impact the growth and proliferation of cancer cell, alter exosome production by breast cancer, and induce immunosuppression in the tumor microenvironment by dampening anti-tumor immunity.
[zotpress userid=’6606345′ items=’6TBDE2XT’ style=’apa’ cite=’yes’]
Genentech announced that the Phase III IMpassion031 study, evaluating Tecentriq® in combination with chemotherapy in comparison to placebo plus chemotherapy, met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response for the treatment of people with early triple-negative breast cancer, regardless of PD-L1 expression.
The authors revealed that YES1 amplification conferred resistance to HER2-targeted drugs.
[British Journal of Cancer]
[zotpress userid=’6606345′ items=’4UGNEI6H’ style=’apa’ cite=’yes’]
Investigators unveiled that LINC00942 exerted its functions as an oncogene in promoting METTL14-mediated m6A methylation and regulating the expression and stability of its target genes CXCR4 and CYP1B1 in breast cancer initiation and progression.
[zotpress userid=’6606345′ items=’N9C7NILE’ style=’apa’ cite=’yes’]
The authors focus on the molecular mechanism and function of glutathione peroxidases in the occurrence and development of breast cancer.
[Journal of Translational Medicine]
[zotpress userid=’6606345′ items=’3SXWZDD5′ style=’apa’ cite=’yes’]